These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12675208)

  • 21. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
    Ferenci P; Formann E; Laferl H; Gschwantler M; Hackl F; Brunner H; Hubmann R; Datz C; Stauber R; Steindl-Munda P; Kessler HH; Klingler A; Gangl A;
    J Hepatol; 2006 Feb; 44(2):275-82. PubMed ID: 16338019
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pegasys: FDA approved Pegasys (peginterferon alfa-2a) for the treatment of hepatitis C].
    Iafolla M
    Sidahora; 2002; (4):8-10. PubMed ID: 12703472
    [No Abstract]   [Full Text] [Related]  

  • 23. Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.
    Hornberger J; Torriani FJ; Dieterich DT; Bräu N; Sulkowski MS; Torres MR; Green J; Patel K
    J Clin Virol; 2006 Aug; 36(4):283-91. PubMed ID: 16765638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Progression of treatment of hepatitis C--peginterferon].
    Pawłowska M; Halota W
    Przegl Epidemiol; 2001; 55 Suppl 3():169-73. PubMed ID: 11984947
    [No Abstract]   [Full Text] [Related]  

  • 25. Second thoughts about secondary analyses.
    Ferenci P
    Dig Liver Dis; 2005 Oct; 37(10):805-7; author reply 808-9. PubMed ID: 16023903
    [No Abstract]   [Full Text] [Related]  

  • 26. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response.
    Malnick SD; Basevitch A
    Gastroenterology; 2006 Aug; 131(2):683; author reply 683-4. PubMed ID: 16890628
    [No Abstract]   [Full Text] [Related]  

  • 27. Peginterferon and ribavirin for chronic hepatitis C.
    Hoofnagle JH; Seeff LB
    N Engl J Med; 2006 Dec; 355(23):2444-51. PubMed ID: 17151366
    [No Abstract]   [Full Text] [Related]  

  • 28. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C.
    Reddy KR; Wright TL; Pockros PJ; Shiffman M; Everson G; Reindollar R; Fried MW; Purdum PP; Jensen D; Smith C; Lee WM; Boyer TD; Lin A; Pedder S; DePamphilis J
    Hepatology; 2001 Feb; 33(2):433-8. PubMed ID: 11172346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiviral effect of peginterferon alfa-2b and alfa-2a compared.
    Jansen PL; Reesink HW
    J Hepatol; 2006 Aug; 45(2):172-3. PubMed ID: 16797101
    [No Abstract]   [Full Text] [Related]  

  • 30. Adverse drug effects and pegylation.
    Wooten JM
    South Med J; 2011 Feb; 104(2):83-4. PubMed ID: 21206333
    [No Abstract]   [Full Text] [Related]  

  • 31. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
    Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
    Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data.
    Cammà C; Di Bona D; Schepis F; Heathcote EJ; Zeuzem S; Pockros PJ; Marcellin P; Balart L; Alberti A; Craxì A
    Hepatology; 2004 Feb; 39(2):333-42. PubMed ID: 14767986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin.
    Buti M; Sanchez-Avila F; Lurie Y; Stalgis C; Valdés A; Martell M; Esteban R
    Hepatology; 2002 Apr; 35(4):930-6. PubMed ID: 11915041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Follow-up of adverse drug reactions from peginterferon alfa-2b-ribavirin therapy.
    Bagheri H; Fouladi A; Barange K; Lapeyre-Mestre M; Payen JL; Montastruc JL; Vinel JP
    Pharmacotherapy; 2004 Nov; 24(11):1546-53. PubMed ID: 15537560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [PEG-interferon alfa 2a against hepatitis C. Better as the standard therapy].
    MMW Fortschr Med; 2001 Nov; 143(44):58. PubMed ID: 11732405
    [No Abstract]   [Full Text] [Related]  

  • 36. A rare complication of pegylated interferon Alfa 2a in a hepatitis C-positive patient on maintenance hemodialysis.
    Satish R; ; Mathew T
    Saudi J Kidney Dis Transpl; 2012 Jan; 23(1):139-42. PubMed ID: 22237239
    [No Abstract]   [Full Text] [Related]  

  • 37. [New perspectives in the treatment of viral hepatitis C: pegylated interferon alpha].
    Alric L; Cacoub P
    Rev Med Interne; 2001 Oct; 22(10):922-5. PubMed ID: 11695314
    [No Abstract]   [Full Text] [Related]  

  • 38. [Sarcoidosis associated with the treatment of hepatitis C: case report and Spanish literature review].
    Trullàs JC; Hernández-Marcet P; Bisbe J
    Med Clin (Barc); 2011 May; 136(14):649-50. PubMed ID: 21051060
    [No Abstract]   [Full Text] [Related]  

  • 39. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin.
    Snoeck E; Wade JR; Duff F; Lamb M; Jorga K
    Br J Clin Pharmacol; 2006 Dec; 62(6):699-709. PubMed ID: 17118125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferon for hepatitis C patients with psychiatric disorders.
    Asnis GM; De La Garza R; Rego SA; Henderson MA; Reinus JF
    Am J Psychiatry; 2004 Dec; 161(12):2332; author reply 2332-4. PubMed ID: 15569920
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.